BioAlliance Pharma's Sitavig® Receives Market Authorization in the U.S. for the Treatment of Herpes Labialis
Published: Apr 16, 2013
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), today announced the receipt of marketing authorization from the U.S. Food and Drug Administration (FDA) for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion to the assessment procedure carried out by the American authorities. After Loramyc ®, registered in 26 countries including the United States, BioAlliance Pharma for the second time has successfully passed the FDA review. The registration of Sitavig, developed internally, shows once again the teams’ capacity and expertise.